A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development-Reference-Cited by-同舟云学术

A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development

Published:2019-10-09 Issue:3 Volume:60 Page:340-350
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Yu Huixin¹,Janssen Julie M.¹,Sawicki Emilia¹,Hasselt J. G. Coen¹,Weger Vincent A.¹,Nuijen Bastiaan¹,Schellens Jan H. M.²,Beijnen Jos H.¹²,Huitema Alwin D. R.¹³

Affiliation:

1. Department of Pharmacy & Pharmacology Netherlands Cancer Institute‐Antoni van Leeuwenhoek Amsterdam The Netherlands

2. Utrecht Institute of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands

3. Department of Clinical Pharmacy University Medical Center Utrecht Utrecht University Utrecht The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1532

Reference29 articles.

1. Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

2. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

3. Pharmacological Effects of Formulation Vehicles

4. Low systemic exposure of oral docetaxel in mice resulting from extensive first‐pass metabolism is boosted by ritonavir;Bardelmeijer HA;Cancer Res,2002

5. Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Cross-sectional Comparative Analysis of Eleven Population Pharmacokinetic Models for Docetaxel in Chinese Breast Cancer Patients;Current Drug Metabolism;2024-08-16

2. Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors;Anti-Cancer Drugs;2022-11-18

3. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?;International Journal of Molecular Sciences;2022-08-30

4. Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies;Cancer Chemotherapy and Pharmacology;2022-07

5. Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir;The Pharmacogenomics Journal;2021-03-01